Pharmaceuticals

Microsoft and Bristol Myers Squibb Partner to Enhance Lung Cancer Detection

Microsoft partners with Bristol Myers Squibb to use AI for early lung cancer detection, targeting underserved areas for better healthcare access.

OTCQX Best 50 2026: Companies Ranked 31-40

OTCQX stocks ranked 31–40 trade on routine, not hype. They are driven by steady cash flow, policy signals, and macro-savvy investor habits.

NVIDIA and Eli Lilly Launch AI Co-Innovation Lab to Transform Drug Discovery

NVIDIA and Lilly are launching an AI lab to redefine drug discovery, with a commitment of up to $1B over five years.

Enhancing Healthcare Operations with OpenAI

OpenAI for Healthcare enhances care quality and reduces administrative tasks while ensuring HIPAA compliance with advanced AI models tailored for healthcare.

OpenEvidence Surges to $12B Valuation After Funding

Trump Admin Cuts Medicare Drug Prices, Impacts Ozempic & Wegovy

Enlivex Therapeutics Initiates Innovative Digital Asset Treasury Strategy

Enlivex Therapeutics invests $212 million into a RAIN-based digital asset treasury, doubling the token’s value and marking a pioneering move.

Mangoceuticals (MGRX) Clinches Deal with Lilly & Novo

Novo Nordisk Stock (NVO): Cuts Forecast

Novo Nordisk shows strong growth in obesity care but faces rising risks and competitive pressures as it heads into 2026.

Hims & Hers Stock Hit Hard—Can Global Growth Save It?

After a 35% stock drop from a Novo Nordisk fallout, Hims & Hers is betting big on global expansion. But will regulators let it bounce back?

Pfizer Files Second Lawsuit Against Novo Nordisk for Metsera

AbbVie Beats Q3 EPS Estimates with $1.86 Results

Thermo Fisher Nears ~$10 B All-Cash Acquisition of Clario, Sources Say

Rockwell Medical to Showcase Hemodialysis Solutions at ASN 2025

Rockwell Medical will exhibit at ASN Kidney Week 2025, showcasing its hemodialysis product portfolio from November 6-9 in Houston.

Novartis Q3 Net Profit Rises 23% on Strong Drug Sales

Novartis posted a 23% profit rise as Kisqali, Kesimpta, and Pluvicto drove sales gains, offsetting U.S. generic pressure. Guidance reaffirmed.